Adcetris® (brentuximab vedotin) is a three component conjugate of antibody and drug that is able to bind, enter, and trigger apoptotic death of CD30-expressing tumour cells.
It is approved to treat relapsed or refractory CD30+ Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL).
The Pharmaceutical Benefits Advisory Committee has recommended Adcetris® for inclusion onto the Pharmaceutical Benefits Scheme for patients with sALCL as it offers a significantly improved potential for salvage and cure, with lower toxicity than existing multi-agent chemotherapy protocols.
Delay in treatment, or dosage reduction of brentuximab, are most commonly caused by peripheral neuropathy and neutropenia, and patients should be monitored for signs of progressive multifocal leukoencephalopathy (PML), tumour lysis syndrome, haematological toxicities and Stevens-Johnson syndrome.
Co-administration with strong CYP3A4/5 and P-glycoprotein inhibitors may increase the incidence of neutropenia, and interactions with other medicines that are CYP3A4/5 inhibitors or inducers should be considered. Combination with bleomycin is contraindicated due to the significant increase of pulmonary toxicity.
Please review full product information before prescribing.